Study Summary
This is a single-arm, open-label clinical study to evaluate the safety, tolerability, and efficacy of U32 injection in patients with acute myeloid leukemia.
Want to learn more about this trial?
Request More InfoInterventions
U32 CAR-TDRUG
Lymphodepletion preconditioning is required prior to CAR-T cell therapy. Lymphodepletion will be performed using a regimen of cyclophosphamide (250-500 mg/m²) and fludarabine (25-30 mg/m²), each administered for 3 consecutive days.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The First Affiliated Hospital of Soochow University, Suzhou, JiangSu 215000 Recruiting | Suzhou | China |